Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis and is used for Candida prophylaxis in hematopoietic stem cell transplantation and other serious fungal infections.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal indicated for serious Candida infections.

- Invasive candidiasis: effective in treating bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves fungal infection of the esophagus in immunocompromised patients. - Candida prophylaxis in hematopoietic stem cell transplantation: prevents invasive Candida disease in transplant recipients.

Micafungin may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Fever - Nausea - Headache - Elevated liver enzymes

Serious or Rare Side Effects: - Hepatotoxicity - Severe hypersensitivity or anaphylaxis - Acute renal failure - Stevens‑Johnson syndrome

Use of Micafungin requires careful clinical monitoring.

- Renal function: assess baseline and monitor during therapy. - Hepatic function: monitor liver enzymes regularly. - Concomitant nephrotoxic drugs: avoid or use with caution. - Immunocompromised patients: watch for breakthrough fungal infections. - Pregnancy and lactation: safety not established; weigh risks versus benefits. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may cause toxicity. - Rifampin: reduces micafungin levels, potentially compromising efficacy. - Strong CYP3A4 inducers (e.g., carbamazepine): may lower micafungin concentrations.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase micafungin levels. - Warfarin: potential alteration of anticoagulant effect. - Statins (e.g., simvastatin): monitor for increased risk of myopathy.